Paulo Falabella

Paulo Falabella

Company: REGENXBIO

Job title: Vice President - Clinical Development & Operations

Seminars:

Initiating Clinical Trials with Gene Therapies Targeting Neurodegenerative Disorders 11:45 am

Clinical Experience with AAV9-based Gene Therapies Targeting Neurodegenerative Disorders Interim analysis of the RGX-121 gene therapy first in human study for the treatment of severe Mucopolysaccharidosis Type II Interim analysis of the RGX-111 gene therapy first in human study and a single patient IND for the treatment of severe Mucopolysaccharidosis Type IRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.